ADAGENE INC. - ADS EACH REPRESENTING 1.25 ORDINAR

Adagene Announces Board and Management Appointments to Support Pipeline Growth

02 Feb 2022 15:05:00 By Nasdaq GlobeNewswire

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

27 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D.

19 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

13 Jan 2022 03:00:00 By Nasdaq GlobeNewswire

Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates

22 Dec 2021 15:05:00 By Nasdaq GlobeNewswire

Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody™

13 Dec 2021 09:23:10 By Nasdaq GlobeNewswire

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

06 Dec 2021 12:49:44 By Nasdaq GlobeNewswire

Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021

06 Dec 2021 05:30:00 By Nasdaq GlobeNewswire

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

29 Nov 2021 15:05:00 By Nasdaq GlobeNewswire

Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021

22 Nov 2021 16:05:50 By Nasdaq GlobeNewswire

Adagene to Participate in Upcoming Investor & Industry Conferences in November

09 Nov 2021 15:05:03 By Nasdaq GlobeNewswire

Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting

04 Nov 2021 08:24:23 By Nasdaq GlobeNewswire

Adagene to Participate in the Jefferies Virtual China Biotech Summit

21 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates

26 Aug 2021 06:45:00 By Nasdaq GlobeNewswire

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)

19 Aug 2021 06:00:00 By Nasdaq GlobeNewswire

Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board

12 Aug 2021 06:45:00 By Nasdaq GlobeNewswire

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

22 Jul 2021 06:45:00 By Nasdaq GlobeNewswire

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million

07 Jul 2021 06:45:00 By Nasdaq GlobeNewswire

Adagene Announces Inclusion in FTSE Russell Indexes

16 Jun 2021 06:45:00 By Nasdaq GlobeNewswire

Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting

19 May 2021 16:05:00 By Nasdaq GlobeNewswire